Credit Suisse Group set a $40.00 price objective on Aimmune Therapeutics (NASDAQ:AIMT) in a research note issued to investors on Monday, Marketbeat Ratings reports. The firm currently has a buy rating on the biotechnology company’s stock.
Several other equities research analysts have also issued reports on the stock. BidaskClub upgraded shares of Aimmune Therapeutics from a sell rating to a hold rating in a research report on Tuesday, August 7th. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a sell rating to a hold rating in a research report on Tuesday, July 24th. Wedbush reiterated an outperform rating and set a $72.00 target price on shares of Aimmune Therapeutics in a research report on Wednesday, May 30th. ValuEngine upgraded shares of Aimmune Therapeutics from a buy rating to a strong-buy rating in a report on Tuesday, May 22nd. Finally, Piper Jaffray Companies started coverage on shares of Aimmune Therapeutics in a report on Friday, May 18th. They issued an overweight rating and a $30.01 price objective for the company. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $52.89.
Aimmune Therapeutics stock traded up $0.07 during mid-day trading on Monday, hitting $28.41. 2,416 shares of the company traded hands, compared to its average volume of 331,708. Aimmune Therapeutics has a one year low of $18.74 and a one year high of $42.00. The firm has a market cap of $1.66 billion, a PE ratio of -10.93 and a beta of -0.24.
In other Aimmune Therapeutics news, CFO Eric Bjerkholt acquired 1,600 shares of the stock in a transaction dated Wednesday, June 13th. The stock was purchased at an average cost of $30.41 per share, for a total transaction of $48,656.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Stephen George Dilly sold 165,374 shares of the business’s stock in a transaction that occurred on Tuesday, June 5th. The stock was sold at an average price of $32.14, for a total transaction of $5,315,120.36. Following the completion of the sale, the insider now owns 376,505 shares of the company’s stock, valued at $12,100,870.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 364,493 shares of company stock valued at $11,580,119. Company insiders own 14.70% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Tiverton Asset Management LLC bought a new stake in shares of Aimmune Therapeutics in the 2nd quarter worth approximately $145,000. Xact Kapitalforvaltning AB bought a new stake in Aimmune Therapeutics during the 1st quarter valued at $207,000. WINTON GROUP Ltd bought a new stake in Aimmune Therapeutics during the 1st quarter valued at $262,000. Fred Alger Management Inc. bought a new stake in Aimmune Therapeutics during the 2nd quarter valued at $269,000. Finally, Wedbush Securities Inc. bought a new stake in Aimmune Therapeutics during the 1st quarter valued at $292,000. Hedge funds and other institutional investors own 80.16% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
See Also: How Short Selling Works
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.